Rosuvastatin calcium and process for producing intermediate thereof
US-2024360086-A1 · Oct 31, 2024 · US
Microbiological process
US10077458B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10077458-B2 |
| Application number | US-201515118924-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 17, 2015 |
| Priority date | Feb 17, 2014 |
| Publication date | Sep 18, 2018 |
| Grant date | Sep 18, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A process for the microbial synthesis of migalastat, specifically a process for the production of migalastat comprising culturing a microorganism under conditions such that at least one imino sugar is produced and detecting and/or isolating an imino sugar produced by said microorganism, and the microorganisms used in this process. The invention also comprises migalastat produced according to the above method and pharmaceutical compositions and uses thereof.
First claim
Opening claim text (preview).
The invention claimed is: 1. A process for the production of migalastat, said process comprising the steps of: (a) culturing a microorganism under conditions, wherein said culturing is carried out by a fermentation process chosen from the group of: batch fermentation; fed-batch fermentation; and continuous fermentation, such that migalastat is produced, and (b) detecting and/or isolating migalastat, wherein said microorganism is chosen from: Streptomyces sp BTA530 (NCIMB 42142) and Streptomyces sp mutant BTM4 (NCIMB 42358). 2. The process as claimed in claim 1 , wherein said detecting step (b) is carried out using an α-galactosidase A activity assay. 3. The process as claimed in claim 1 , wherein said microorganism is cultured in a medium comprising lactose.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
having a hydrogen atom as the second substituent in position 4 · CPC title
- C12P17/12Primary
containing a six-membered hetero ring · CPC title
Alpha-galactosidase (3.2.1.22) · CPC title
Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10077458B2 cover?
- A process for the microbial synthesis of migalastat, specifically a process for the production of migalastat comprising culturing a microorganism under conditions such that at least one imino sugar is produced and detecting and/or isolating an imino sugar produced by said microorganism, and the microorganisms used in this process. The invention also comprises migalastat produced according to th…
- Who is the assignee on this patent?
- Glaxosmithkline Ip Dev Ltd
- What technology area does this patent fall under?
- Primary CPC classification C12P17/12. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).